{"prompt": "['Alliance A171601', '155.', 'Wilborn TW, Lang NP, Smith M, Meleth S, Falany CN. Association of SULT2A1 allelic variants', 'with plasma adrenal androgens and prostate cancer in African-Americanmen. J Steroid Biochem', 'Mol Biol. 2006 Jun;99(4-5):209-14 PubMed PMID: 16617014.', '156.', 'Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA. Androgen', 'metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol. 2012', 'Aug;36(4):347-53. doi: 0.1016/j.canep.2012.04.002. PubMed PMID: 22542949; PubMed', 'Central PMCID: PMC3392409.', '157.', 'Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, et al: Associations between genetic', 'variants and the effect of letrozole and exemestane on bone mass and bone turnover. Breast', 'Cancer Res Treat. 2015 Nov; 154(2):263-73. doi: 10.1007/s10549-015-3608-8.1 PubMed PMID:', '26536870; PubMed Central PMCID: PMC4807610.', '158.', 'Leyland-Jones B, Gray KP, Abramovitz M, Bouzyk M, Young B, et al; BIG 1-98 Collaborative', 'Group ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole', 'versus tamoxifen or their sequence for early breast cancer. Breast Cancer Res Treat. 2015', 'Dec;154(3):543-55.doi:10.1007/s10549-015-3634-6 PubMed PMID: 26590813; PubMed', 'Central PMCID:PMC4730949.', '159.', 'Artigal\u00c3\u00a1S O, Vanni T, Hutz MH, Ashton-Prolla P, Schwartz IV. Influence of CYP19A1', 'polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review', 'and meta-analysis. BMC Med. 2015 Jun 1;13:139.doi: 10.1186/s12916-015-0373-9. PubMed', 'PMID: 26067721; PubMed Central PMCID:PMC4475294', '160.', 'Raunio H, etal Br J Clin Pharmacol 2001 Oct; 52(4): 357-363', '161.', 'Beal, S. and L. Sheiner, NONMEM Users Guide. 1992, NONMEM Project Group, University of', 'California at San Francisco: San Francisco', '86', 'NCIVersion Date: 5/29/2020', 'Update 5']['Alliance A171601', '17.0 MODEL CONSENT FORM', 'Study Title for Study Participants:', 'Testing the effects of palbociclib and fulvestrant or letrozole for patients', '70 years of age and older with metastatic breast cancer', 'Official Study Title for Internet Search on http://www.ClinicalTrials.gov', 'Alliance A171601: A Phase II Trial Assessing the tolerability of Palbociclib in', 'combination with letrozole or fulvestrant in patients aged 70 and older with', 'estrogen receptor positive, HER-2 negative metastatic breast cancer', 'This study is conducted by the Alliance for Clinical Trials in Oncology, a national clinical', 'research group supported by the National Cancer Institute This study has public funding from the', 'National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United', 'States Department of Health and Human Services. The Alliance is made up of cancer doctors,', 'health professionals, and laboratory researchers, whose goal is to develop better treatments for', 'cancer, to prevent cancer, to reduce side effects from cancer, and to improve the quality of life of', 'cancer patients.', 'What is the usual approach to my breast cancer?', 'We are asking you to take part in this study because you are 70 years old or over and have been', 'recently diagnosed with estrogen receptor positive, HER2 negative metastatic breast cancer.', 'Patients with this metastatic breast cancer are usually treated with a drug called palbociclib along', 'with a hormonal agent, either fulvestrant or letrozole, as determined by your doctor. Palbociclib', 'and letrozole are given by mouth and fulvestrant is an injection. This study follows the usual', 'Food and Drug Administration (FDA) approved treatment, but we are conducting this study', \"because we don't know if older patients have more side effects than younger patients.\", 'What are my other choices ifl do not take part in this study?', 'If you decide not to take part in this study, you have other choices. For example:', 'You may choose to have the usual approach described above without being in a', 'study.', 'You may choose to take part in a different study, if one is available.', 'You may choose not to be treated for cancer and may want to receive comfort care to', 'relieve symptoms.', 'Why is this study being done?', 'The purpose of this study is to find out the side effects that the standard, FDA-approved', 'combination treatment of letrozole or fulvestrant and palbociclib has on patients 70 years old and', 'over. Palbociclib given along with letrozole or fulvestrant instead of letrozole or fulvestrant', '87', 'NCI Version Date: 5/29/2020', 'Update 5']\n\n###\n\n", "completion": "END"}